Ignite Creation Date:
2024-05-06 @ 4:04 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04863703
Status:
RECRUITING
Last Update Posted:
2023-03-10
First Post:
2021-04-13
Brief Title:
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta IMPHROVE-D
Sponsor:
Hannover Medical School
Organization:
Hannover Medical School
Study Overview
Official Title:
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta IMPHROVE-D
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMPHROVE-D
Brief Summary:
Portal hypertension PH is one of the key drivers of clinical deteoration in patients with liver cirrhosis It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH and is associated with an improved outcome Recently Bulevirtide was approved for the treatment of patients coinfected with hepatitis B HBV and chronic hepatitis delta HDV infection which helps to achieve viral supression in these patients This study investigates the potential effects of viral supression on PH in patients with chronic HBVHDV infection and liver cirrhosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None